SCHEMBL30101544

SCHEMBL30101544

c1cc2c(c(OC3CCCOC3)c1)CNC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QPCT Q16769 1/20 0.37
QPCTL Q9NXS2 1/20 0.37
HTR2C P28335 1/20 0.34
HTR2B P41595 1/20 0.34
MKNK2 Q9HBH9 2/20 0.33
EIF4E P06730 1/20 0.33
MKNK1 Q9BUB5 1/20 0.33
NTRK1 P04629 1/20 0.32
NTRK3 Q16288 1/20 0.32
NTRK2 Q16620 1/20 0.32
TIPARP Q7Z3E1 2/20 0.32
CNR2 P34972 1/20 0.31
TBK1 Q9UHD2 1/20 0.31
PDE4A P27815 4/20 0.31
PDE4B Q07343 4/20 0.31
PDE4C Q08493 4/20 0.31
PDE4D Q08499 4/20 0.31
CHEK1 O14757 2/20 0.31
BRD4 O60885 1/20 0.31
HTR1A P08908 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30156626 0.92 NTRK1 (0.38) QPCTQPCTLNTRK1NTRK3NTRK2
Hydrochloric Acid SCHEMBL31014071 0.90 NTRK1 (0.37) QPCTQPCTLNTRK1NTRK3NTRK2
SCHEMBL30101464 0.83 KAT2B (0.43) QPCTQPCTLHTR2CHTR2BMKNK2
Hydrochloric Acid SCHEMBL31013890 0.79 PNMT (0.42)
SCHEMBL30101395 0.78 MCHR1 (0.43) HTR2CHTR2BCHEK1BRD4SLC6A2
SCHEMBL29942325 0.77 HRH1 (0.51) TIPARPHTR1ASLC6A2SLC6A4SLC6A3
SCHEMBL30101397 0.74 HTR1A (0.50) HTR2CHTR2BTIPARPHTR1ASLC6A2
SCHEMBL24913826 0.74 TIPARP (0.46) MKNK2MKNK1TIPARPCNR2
SCHEMBL30101459 0.74 TIPARP (0.46) MKNK2MKNK1TIPARPCNR2
SCHEMBL17585072 0.71 CD44 (0.49) HTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS, INC. 2025-01-30 US disclosed
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2023-06-22 US disclosed
US-11566020-B1 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2023-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 QPCT 1635/4885QPCTL 2941/4885HTR2C 1340/4885
US-11566020-B1 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 QPCT 1635/4885QPCTL 2941/4885HTR2C 1340/4885
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 QPCT 1635/4885QPCTL 2941/4885HTR2C 1340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.